Protalix BioTherapeutics Inc.

PLX | AMEX

Price Alert Chart Builder DCF Calculator

$2.79

+$0.04 (+1.27%)

Sep 22, 2026, 11:05 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.27%

(1D)

Rating

Updated: Aug 12, 2026

67.5

Fundamentals Strong

Market Sentiment Bullish

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $224.39M

1D Range

2.75 2.83

52W Range

1.60 3.19

Valuation (TTM)

PE 11.96

PB 3.10

EV/EBITDA 7.74

Valuation (NTM)

Forward PE 54.39

Forward PEG -0.14

Price Target $6

Cash Flow

FCF Yield 3.5%

SBC Adj. FCF Yield 2.4%

SBC Impact -29.5%

Margins

Gross Margin 69.2%

Operating Margin 28.9%

FCF Margin 9.5%

Growth (CAGR)

Revenue 3Y | 5Y 6.1% | 10.9%

Dil EPS 3Y | 5Y 137.4% | 245.1%

FCF 3Y | 5Y 42321.4% | 102.2%

Returns

ROA 17.2%

ROE 31.6%

ROIC 23.3%

Financial Health

Net Cash

$27.42M

Current Ratio 2.94

Interest Coverage 18.63

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based p...

Sector Healthcare

Industry Biotechnology

Employees 226

IPO Date May 14, 1998

Website www.protalix.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+115.05%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞